The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC

Summary: The mechanisms of osimertinib resistance have not been well characterized. We conducted next-generation sequencing to recognize novel resistance mechanism and used cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models to evaluate the anti-proliferative effects of aspi...

Full description

Bibliographic Details
Main Authors:	Rui Han, Caiyu Lin, Chong Zhang, Jun Kang, Conghua Lu, Yiming Zhang, Yubo Wang, Chen Hu, Yong He
Format:	Article
Language:	English
Published:	Elsevier 2023-07-01
Series:	iScience
Subjects:	Molecular genetics Molecular interaction Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589004223011823

Similar Items

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction
by: Rui Han, et al.
Published: (2020-06-01)

Overcoming MET-mediated resistance in oncogene-driven NSCLC
by: Nadine Reischmann, et al.
Published: (2023-07-01)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
by: Michael Cekay, et al.
Published: (2023-08-01)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
by: Jingran Ji, MD, et al.
Published: (2023-03-01)

Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis
by: Guojin Zhou, et al.
Published: (2024-01-01)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
by: Fionnuala Crowley, MB BCh BAO, et al.
Published: (2022-01-01)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
by: Kana Watanabe, et al.
Published: (2023-08-01)

Targeted therapeutic options in early and metastatic NSCLC-overview
by: Gabriella Gálffy, et al.
Published: (2024-03-01)

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
by: Anita J.W. M. Brouns, MD, et al.
Published: (2023-05-01)

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib
by: Waleed Kian, et al.
Published: (2023-02-01)

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
by: Yuki Takeyasu, MD, et al.
Published: (2024-02-01)

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
by: Judith L. Gulikers, MSc, et al.
Published: (2024-04-01)

Validation of CRC and NSCLC somatic mutations detected by NGS using ddPCR
by: Lana Salihefendić, et al.
Published: (2019-06-01)

Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFR<sup>L858R/T790M</sup> Mutations
by: Moamen A. Hassanin, et al.
Published: (2022-07-01)

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
by: Molly Wilgucki, DO, et al.
Published: (2022-10-01)

Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
by: Amol Gupta, et al.
Published: (2023-03-01)

Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy
by: Pasquale Pisapia, et al.
Published: (2022-08-01)

Adenovirus pneumonia mimicking osimertinib‐induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report
by: Toru Imai, et al.
Published: (2024-03-01)

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
by: M. Jebbink, MD, et al.
Published: (2023-04-01)

Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR‐mutated NSCLC
by: Yusuke Hamakawa, et al.
Published: (2023-09-01)

RTEL1 and MCM10 overcome topological stress during vertebrate replication termination
by: Lillian V. Campos, et al.
Published: (2023-02-01)

Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report
by: Liu Z, et al.
Published: (2023-07-01)

Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations
by: Miaomiao Li, et al.
Published: (2022-06-01)

Contribution of the Idylla<sup>TM</sup> System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of <i>EGFR</i> Mutations
by: Constance Petiteau, et al.
Published: (2021-11-01)

PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC
by: Kavya Sri Racherla, et al.
Published: (2023-07-01)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
by: Qiuyue Ye, et al.
Published: (2023-05-01)

Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
by: Zachary Schrank, et al.
Published: (2018-07-01)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
by: Silvia La Monica, et al.
Published: (2020-12-01)

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
by: Qiong Qin, et al.
Published: (2020-09-01)

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
by: Diego Enrico, MD, et al.
Published: (2023-02-01)

Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668]
by: Tianyao Lei, et al.
Published: (2023-10-01)

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
by: Guangrui Li, et al.
Published: (2023-10-01)

Review of published 467 achondroplasia patients: clinical and mutational spectrum
by: XinZhong Zhang, et al.
Published: (2024-01-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
by: Jiao‐Li Wang, et al.
Published: (2022-11-01)

Overcoming the Negligence in Laboratory Diagnosis of Mucosal Leishmaniasis
by: Lilian Motta Cantanhêde, et al.
Published: (2021-09-01)

Designing molecular diagnostics for current tuberculosis drug regimens
by: Sophia B. Georghiou, et al.
Published: (2023-12-01)

Targeting potential receptor molecules in non-small cell lung cancer (NSCLC) using in silico approaches
by: C. Kirubhanand, et al.
Published: (2023-02-01)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
by: A.J. Piper-Vallillo, MD, et al.
Published: (2022-06-01)

Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1
by: Daniel J.L. Coleman, et al.
Published: (2024-04-01)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
by: Jennifer Novak, et al.
Published: (2022-08-01)